Clinical Trial

Organ-Preserving Endoscopic Resection & Adjuvant RADIO-immuno-chemotherapy for Esophageal Cancer

Study acronym: OPERARADIO
Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The goal of this study is to assess the safety of delivering concurrent adjuvant chemoradiation or immuno-radiation therapy after EMR/ESD in pT1b/T2N0 esophageal cancer patients. The main objectives of the study are: 1. Assess the feasibility of enrolling 10 patients. 2. Assess the safety of delivering concurrent adjuvant chemoradiation or immunoradiation therapy after EMR/ESD in pT1b/T2 esophageal cancer patients
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2022-12-19; most recent amendment 2026-05-05.
Status change: Recruiting → Active, Not Recruiting 2024-10-25
Status change: Not Yet Recruiting → Recruiting 2024-04-05
Trial Details
NCT Number NCT05667298
Lead Sponsor University of Manitoba
Collaborators: Manitoba Medical Service Foundation, CancerCare Manitoba, AstraZeneca
Conditions Esophageal Cancer
Enrollment 11 participants
Start Date 2023-03-01
Primary Completion 2025-06-20 (estimated)
Study Completion 2029-07-01 (estimated)
Updated on ClinicalTrials.gov 2026-05-11